English | Español
Patient Daily | Feb 6, 2026

GSK focuses on complications from obesity rather than GLP-1 drugs
Patient Daily | Feb 6, 2026

Eli Lilly sees opportunity as Novo Nordisk's oral Wegovy expands obesity drug market
Patient Daily | Feb 6, 2026

Congressman questions transparency of FDA's priority voucher program
Patient Daily | Feb 6, 2026

Eli Lilly expands tirzepatide trials into immunology with combination therapies
Patient Daily | Feb 6, 2026

AbbVie stresses growth beyond immunology as Skyrizi and Rinvoq lead 2025 sales
Patient Daily | Feb 6, 2026

Rare disease drug development sees growth amid regulatory changes
Patient Daily | Feb 6, 2026

Novo Nordisk focuses on Wegovy pill launch amid rising competition and declining sales outlook
Patient Daily | Feb 6, 2026

Penn Medicine workshop uses writing as therapy for cancer patients

Trending
+ Regulatory
B. D. Benavides | Mar 18, 2026

Taxpayer advocate: Instead of improving product safety, litigation can result in the ‘opposite because runaway legal costs deter innovation'
+ Pharmaceuticals
Patient Daily | Mar 22, 2026

BioMarin pauses dosing and enrollment in two Voxzogo studies after safety signal
+ Regulatory
Patient Daily | Mar 20, 2026

Neurosurgeon DiGiorgio on 340B: '340B also takes money from taxpayers and makes everyone’s health insurance more expensive'
+ Pharmaceuticals
Patient Daily | Mar 22, 2026

FDA rejects REGENXBIO’s Hunter syndrome therapy as Denali awaits decision on rival drug